Print this page
-
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol.
Protocol: 111706Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified -
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site
- 1
- 2